Spectral Medical Inc. (EDTXF)

Market Cap	235.85M -19.7%
Revenue (ttm)	1.53M -19.8%
Net Income	-243.72K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,500
Open	0.7499
Previous Close	0.6827
Day's Range	0.7499 - 0.8145
52-Week Range	0.6382 - 1.1000
Beta	0.19
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Spectral Medical

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, an...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1991
• Employees: 29
• Stock Exchange: OTCMKTS
• Ticker Symbol: EDTXF

Financial Performance

In 2025, Spectral Medical's revenue was 2.44 million, an increase of 6.82% compared to the previous year's 2.29 million. Losses were -47.69 million, 209.6% more than in 2024.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error